Dhippayom Teerapon, Walker Roger
Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, Wales, CF10 3XF, UK.
Pharm World Sci. 2006 Aug;28(4):194-8. doi: 10.1007/s11096-006-9031-9. Epub 2006 Oct 26.
To investigate if the reclassification of omeprazole from a prescription only medicine to pharmacy sale status had an impact on the prescribing and sales of ulcer-healing drugs and whether deprivation had any influence on this.
Primary care, Wales, UK.
Retrospective analysis (March 2002 to February 2005) of prescription data and pharmacy sales data.
Number of items per 1,000 population.
The number of prescription items for ulcer-healing drugs across Wales increased in each year of the study. The number of items per 1,000 population for proton pump inhibitors increased by 12.4% (473.3 to 531.8 items) in 2003/04 and 13.8% (531.8 to 605.1 items) in 2004/05, whereas the number of items per 1,000 population for H2 antagonists fell by 6.2% (149.1 to 139.9 items), and 5.7% (139.9 to 131.9 items) during 2003/04 and 2004/05, respectively. The sale of items per 1,000 population of H(2) antagonists increased by 34.3% (19.8 to 26.6 items) in 2003/04, but fell by 8.6% (26.6 to 24.3 items) in 2004/05. In February 2005, 12 months after reclassification, omeprazole accounted for 7.6% (2.0 items per 1,000 population) of the total sales (26.3 items per 1,000 population) of ulcer-healing drugs from pharmacies in Wales. Areas with high multiple deprivation and unemployment were significantly associated with the prescribing of ulcer-healing drugs, H2 antagonists and proton pump inhibitors. Multiple deprivation, unemployment and low income explained 21% of the variation in prescribing of ulcer-healing drugs. The sale of omeprazole through pharmacies was not related to these deprivation characteristics.
Twelve months after the reclassification of omeprazole the market growth of H2 antagonists sold from pharmacies was halted although there was no apparent impact on the prescription of ulcer-healing drugs. As a consequence there was no saving to the health service drug budget associated with the reclassification of omeprazole.
调查奥美拉唑从仅需处方的药品重新分类为可在药店销售的药品后，是否对溃疡愈合药物的处方和销售产生影响，以及贫困状况对此是否有任何影响。
英国威尔士的初级医疗保健机构。
对2002年3月至2005年2月的处方数据和药店销售数据进行回顾性分析。
每千人口的药品数量。
在研究的每一年中，威尔士溃疡愈合药物的处方数量均有所增加。2003/04年度，质子泵抑制剂每千人口的药品数量增加了12.4%（从473.3增加到531.8），2004/05年度增加了13.8%（从531.8增加到605.1）；而H2拮抗剂每千人口的药品数量在2003/04年度下降了6.2%（从149.1降至139.9），2004/05年度下降了5.7%（从139.9降至131.9）。2003/04年度，H2拮抗剂每千人口的销售量增加了34.3%（从19.8增加到26.6），但在2004/05年度下降了8.6%（从26.6降至24.3）。在重新分类12个月后的2005年2月，奥美拉唑占威尔士药店溃疡愈合药物总销售量（每千人口26.3）的7.6%（每千人口2.0）。多重贫困和失业率高的地区与溃疡愈合药物、H2拮抗剂和质子泵抑制剂的处方显著相关。多重贫困、失业和低收入解释了溃疡愈合药物处方差异的21%。通过药店销售的奥美拉唑与这些贫困特征无关。
奥美拉唑重新分类12个月后，药店销售的H2拮抗剂的市场增长停止，尽管对溃疡愈合药物的处方没有明显影响。因此，奥美拉唑的重新分类并未给医疗服务药品预算带来节省。
